Migraine Clinical Trial
— IMAGINEOfficial title:
Interactive Music And Guided Imagery for Nonpharma Headache Ease
The purpose of this study is to determine feasibility and acceptability of telehealth music imagery for migraine (Aim 1) and to explore whether there are clinically meaningful changes in headache frequency and associated patient-centered outcomes (Aim 2).
Status | Not yet recruiting |
Enrollment | 25 |
Est. completion date | August 15, 2025 |
Est. primary completion date | June 15, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - A migraine headache ICD-10 diagnosis, and confirmed by the American Migraine Prevalence and Prevention (AMPP) assessment. - Completion of at least 28 headache diary days - A confirmed frequency of =4 headache days per month - Confirmed access to a smartphone, computer/tablet - A primary pain complaint of headache. Patients must be stabilized on their headache medications. Patients must be on their current headache medications for the last 3 months and have no known future changes to those medications for the next 3 months from the start of enrollment. Exclusion Criteria: - Non-Veterans - Veterans without a migraine headache ICD-10 diagnosis - Veterans without a migraine headache confirmation from AMPP - Veterans whose primary pain complaint is not headache - Veterans who do not speak English - Veterans with a significant cognitive impairment based on EHR ICD10 diagnosis [Mild Cognitive Impairment G31.84; Dementia F03.90; Alzheimer's Dementia G30.9] and confirmed by the Short Portable Mental Status Questionnaire (SPMSQ)19 cognitive screener during the initial baseline assessment. Veterans with a hearing deficit that would impair participation in the MI intervention - Veterans who have a diagnosis of Traumatic Brain Injury = 1 year before diagnosis of migraine or worsening of migraine as indicated by post-traumatic headache screening tool - Veterans currently suffering from a disabling psychiatric illness (as noted by clinician); or psychiatric hospitalization in the last 6 months - Veterans who have active psychotic symptoms, suicidality, or severe depressive symptoms (PHQ score >20) per patient report and/or EHR notes - Veterans who have had suicidal and/or homicidal ideation in the past 6 months. - Veterans who decline to or cannot pass the tech screening4b - Veterans receiving hospice or palliative care - Veterans who do not have access to smartphone, computer/tablet |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Richard L. Roudebush VA Medical Center | VA Connecticut Healthcare System |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility metrics | Percentage of contacted and eligible Veterans consent to study participation, attend intervention sessions, and complete the treatment protocol and scheduled outcome assessments | 2 months | |
Primary | Acceptability interviews | Veterans will be interviewed after completing study sessions to assess experiences of telehealth MI; aspects of the intervention, especially virtually delivery, that Veterans perceive to be most/least helpful or most/least liked; barriers and facilitators to study participation; how the music interventions compare to other migraine treatments already tried. | 6 month | |
Secondary | Headache Diary | Log of headache frequency and characteristics | Baseline and 3 months | |
Secondary | Music Diary | Log of music listening frequency | During active music intervention (months 1-2) | |
Secondary | Patient Health Questionnaire (PHQ-9) | Depression, self-reported assessment | 3 month | |
Secondary | Migraine Disability Assessment | 5 item self reported assessment for headache-related disability | baseline and 3 month | |
Secondary | Veterans RAND 12-item (VR-12) | 12-item, self-report measure of health-related quality life | baseline and 3 month | |
Secondary | Generalized Anxiety Disorder Screener (GAD-7) | 7-item, self-report measure of anxiety | baseline and 3 month | |
Secondary | Post-Traumatic Stress Disorder Checklist (PCL-5) | a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD | baseline and 3 month | |
Secondary | Headache Pain Catastrophizing Scale (HPCS) | The HPCS is a 13-item self-report measure of catastrophic thinking related to headache | baseline and 3 month | |
Secondary | Headache Management Self-Efficacy Scale (HMSE) | a 25-item self-report questionnaire related to a person's confidence in their ability to manage their headache symptoms | baseline and 3 month | |
Secondary | Patient Global Perception of Change (PGPC) | single item scale measures the participant's perception of improvement since the start of the study | 3 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |